yahoo_financeOriginal article
Celcuity Says Gedatolisib Outperforms Novartis' Alpelisib Plus Fulvestrant in Phase 3 Trial
Phase 3positiveGedatolisibAlpelisibFulvestrantPositive
AI Analysis
Summary
Celcuity announced positive Phase 3 trial results showing Gedatolisib outperformed Novartis' Alpelisib plus Fulvestrant combination therapy.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Gedatolisib outperformed Novartis' Alpelisib plus Fulvestrant combination
Importance:7/10
Sentiment:
0.80
Phase_3_DataClinical_TrialOncologyCompetitive_Comparison
Related Companies
Read the original article
Published by yahoo_finance on June 2, 2026 7:09 PM